ImmunityBio (IBRX) Competitor Comparison
We are evaluating the key criteria listed to compare ImmunityBio (IBRX) against its competitors in the Biotechnology industry.
Market Capitalization
58 / 368Gross Profits
140 / 278Total Revenue
249 / 300EBITDA
309 / 337Free Cashflow
331 / 352Quick Ratio
286 / 357Earnings per Share
132 / 359Dividend yield
0 / 6Total Cash
164 / 358Performance 3 years
135 / 368Performance 5 years
24 / 368Performance 10 years
226 / 368Linearity 3 years
57 / 368Linearity 5 years
173 / 368Linearity 10 years
261 / 368Total Rank
324 / 368Dividend Rank
158 / 368Valuation Rank
286 / 368Piotroski Rank
289 / 368Muliplier Rank
363 / 368Market Capitalization - IBRX ranking 58 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.